Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06199934 · ClinicalTrials.gov registry record
Effectiveness of BNT162b2 Formulations Using State Vaccine Registry and Insurance Claims Data
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 19,853,610
- Enrollment target
NCT06199934 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 19,853,610 participants.
The verdict
NCT06199934 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 19,853,610 participants
- Enrollment target
Study Summary
The primary purpose of this study is to learn about how well different versions of the Pfizer-BioNTech COVID-19 vaccine (called BNT162b2) work at preventing death, severe COVID-19 that requires a trip to the hospital, and overall use of healthcare resources, such as needing to go the doctor or urgent care due to illness. Pfizer is not enrolling any participants for this study. Instead, existing data from different health data sources will be used to help answer the scientific questions Pfizer is interested in learning more about.
Interventions
- BIOLOGICAL Vaccination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19,853,610 participants |
| Start Date | 2023-09-11 |
| Est. Completion | 2024-07-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06199934
The ClinicalTrials.gov registry entry for NCT06199934 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 19,853,610 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vaccination is the first listed.
NCT06199934 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06199934 about?
NCT06199934 is a clinical study titled "Effectiveness of BNT162b2 Formulations Using State Vaccine Registry and Insurance Claims Data". The primary purpose of this study is to learn about how well different versions of the Pfizer-BioNTech COVID-19 vaccine (called BNT162b2) work at preventing death, severe COVID-19 that requires a trip to the hospital, and overall use of healthcare resources, such as needing to go the doctor or urgen...
What is the current status of trial NCT06199934?
This trial is currently completed. The enrollment target is 19,853,610 participants. The study started on 2023-09-11. Estimated completion is 2024-07-31.
What interventions are being tested in trial NCT06199934?
The interventions under investigation include: Vaccination (BIOLOGICAL).
Who is sponsoring clinical trial NCT06199934?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.